Targeting apoptosis pathways by Celecoxib in cancer - PubMed (original) (raw)
Review
. 2013 May 28;332(2):313-24.
doi: 10.1016/j.canlet.2011.01.012. Epub 2011 Feb 22.
Affiliations
- PMID: 21345578
- DOI: 10.1016/j.canlet.2011.01.012
Review
Targeting apoptosis pathways by Celecoxib in cancer
Verena Jendrossek. Cancer Lett. 2013.
Abstract
Celecoxib is a paradigmatic selective inhibitor of cyclooxygenase-2 (COX-2). This anti-inflammatory drug has potent anti-tumor activity in a wide variety of human epithelial tumor types, such as colorectal, breast, non-small cell lung, and prostate cancers. Up to now, the drug found application in cancer prevention in patients with familial adenomatous polyposis. Moreover, the use of Celecoxib is currently tested in the prevention and treatment of pancreatic, breast, ovarian, non-small cell lung cancer and other advanced human epithelial cancers. Induction of apoptosis contributes to the anti-neoplastic activity of Celecoxib. In most cellular systems Celecoxib induces apoptosis independently from its COX-2 inhibitory action via a mitochondrial apoptosis pathway which is however, not inhibited by overexpression of Bcl-2. In addition, Celecoxib exerts antagonistic effects on the anti-apoptotic proteins Mcl-1 and survivin. Consequently, the use of Celecoxib may be of specific value for the treatment of apoptosis-resistant tumors with overexpression of Bcl-2, Mcl-1, or survivin as single drug or in combination with radiotherapy, chemotherapy, or targeted pro-apoptotic drugs that are inhibited by survivin, Bcl-2 or Mcl-1. As COX-2 inhibition has been associated with cardiovascular toxicity, the value of drug derivatives without COX-2 inhibitory action should be validated for prevention and treatment of human epithelial tumors to reduce the risk for heart attack or stroke. However, its additional COX-2 inhibitory action may qualify Celecoxib for a cautious use in COX-2-dependent epithelial tumors, where the drug could additionally suppress COX-2-mediated growth and survival promoting signals from the tumor and the stromal cells.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.
Similar articles
- Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt.
Liu B, Shi ZL, Feng J, Tao HM. Liu B, et al. Cell Biol Int. 2008 May;32(5):494-501. doi: 10.1016/j.cellbi.2007.10.008. Epub 2007 Nov 5. Cell Biol Int. 2008. PMID: 18078766 - Celecoxib activates a novel mitochondrial apoptosis signaling pathway.
Jendrossek V, Handrick R, Belka C. Jendrossek V, et al. FASEB J. 2003 Aug;17(11):1547-9. doi: 10.1096/fj.02-0947fje. Epub 2003 Jun 17. FASEB J. 2003. PMID: 12824303 - Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo.
Pyrko P, Soriano N, Kardosh A, Liu YT, Uddin J, Petasis NA, Hofman FM, Chen CS, Chen TC, Schönthal AH. Pyrko P, et al. Mol Cancer. 2006 May 18;5:19. doi: 10.1186/1476-4598-5-19. Mol Cancer. 2006. PMID: 16707021 Free PMC article. - Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs.
Schönthal AH, Chen TC, Hofman FM, Louie SG, Petasis NA. Schönthal AH, et al. Expert Opin Investig Drugs. 2008 Feb;17(2):197-208. doi: 10.1517/13543784.17.2.197. Expert Opin Investig Drugs. 2008. PMID: 18230053 Review. - Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention.
Kismet K, Akay MT, Abbasoglu O, Ercan A. Kismet K, et al. Cancer Detect Prev. 2004;28(2):127-42. doi: 10.1016/j.cdp.2003.12.005. Cancer Detect Prev. 2004. PMID: 15068837 Review.
Cited by
- Utilizing topological indices in QSPR modeling to identify non-cancer medications with potential anti-cancer properties: a promising strategy for drug repurposing.
Yousaf S, Shahzadi K. Yousaf S, et al. Front Chem. 2024 Aug 8;12:1410882. doi: 10.3389/fchem.2024.1410882. eCollection 2024. Front Chem. 2024. PMID: 39176073 Free PMC article. - Celecoxib and Bcl-2: emerging possibilities for anticancer drug design.
Winfield LL, Payton-Stewart F. Winfield LL, et al. Future Med Chem. 2012 Mar;4(3):361-83. doi: 10.4155/fmc.11.177. Future Med Chem. 2012. PMID: 22393942 Free PMC article. Review. - α-Conotoxins Enhance both the In Vivo Suppression of Ehrlich carcinoma Growth and In Vitro Reduction in Cell Viability Elicited by Cyclooxygenase and Lipoxygenase Inhibitors.
Osipov AV, Terpinskaya TI, Yanchanka T, Balashevich T, Zhmak MN, Tsetlin VI, Utkin YN. Osipov AV, et al. Mar Drugs. 2020 Apr 7;18(4):193. doi: 10.3390/md18040193. Mar Drugs. 2020. PMID: 32272633 Free PMC article. - Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases.
Hardaway AL, Herroon MK, Rajagurubandara E, Podgorski I. Hardaway AL, et al. Cancer Metastasis Rev. 2014 Sep;33(2-3):527-43. doi: 10.1007/s10555-013-9484-y. Cancer Metastasis Rev. 2014. PMID: 24398857 Free PMC article. Review. - A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery.
Pillaiyar T, Meenakshisundaram S, Manickam M, Sankaranarayanan M. Pillaiyar T, et al. Eur J Med Chem. 2020 Jun 1;195:112275. doi: 10.1016/j.ejmech.2020.112275. Epub 2020 Apr 2. Eur J Med Chem. 2020. PMID: 32283298 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials